Financial Cellular Biomedicine Group Announces Closing of $43.13 Million Strategic Investment from Dangdai International Group Co., Limited, a Wholly-Owned Hong Kong Subsidiary of Wuhan Dangdai Science & Technology Industries Group Inc. byJosh SandbergApril 20, 2016
